Trial Profile
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Sym 021 (Primary) ; Sym-022 (Primary) ; Sym-023 (Primary)
- Indications Ductal carcinoma; Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Symphogen
- 21 Apr 2022 Status changed from active, no longer recruiting to completed.
- 04 Nov 2021 Planned End Date changed from 1 Nov 2021 to 1 Oct 2022.
- 04 Nov 2021 Planned primary completion date changed from 1 Nov 2021 to 1 Oct 2022.